Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
Facteur d'impact: 2.9 Facteur d'impact sur 5 ans: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimer: 0743-4863
ISSN En ligne: 2162-660X

Volumes:
Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v19.i2.20
35 pages

Oral Delivery of Proteins: Progress and Prognostication

Rakhi B. Shah
Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Science Center, Amarillo, TX 79106
Fakhrul Ahsan
Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, USA
Mansoor A. Khan
Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Science Center, Amarillo, TX 79106

RÉSUMÉ

The delivery of proteins has gained momentum with the development of biotechnology sector that provided large-scale availability of therapeutic proteins. The availability is mostly due to the advances in recombinant DNA technology. The low oral bioavailability, however, continues to be a problem for several proteins because of their large molecular size, low permeation through biological membranes, and susceptibility to molecular changes in both biological and physical environments. The demand for effective delivery of proteins by the oral route has brought a tremendous thrust in recent years both in the scope and complexity of drug delivery technology. The important therapeutic proteins and peptides being explored for oral delivery include insulin, calcitonin, interferons, human growth hormone, glucagons, gonadotropin-releasing hormones, enkephalins, vaccines, enzymes, hormone analogs, and enzyme inhibitors. This article reviews the progress in oral delivery of these proteins, provides comments on the strategies to improve their oral bioavailability, and highlights their current market trends.


Articles with similar content:

Nanostructured Lipid Carriers: A New Paradigm in Topical Delivery for Dermal and Transdermal Applications
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 4
Gajanand Sharma, Bhupinder Singh, Kaisar Raza, Om Parkash Katare, Kanika Thakur
Recent Developments of Biodegradable and Biocompatible Materials Based Micro/Nanoparticles for Delivering Macromolecular Therapeutics
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.26, 2009, issue 1
Guihua Huang, Yang Shi
Peptide and Protein Delivery Using New Drug Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 4
Ashish Jain, Satish Shilpi, Pooja Hurkat, Aviral Jain, Arvind Gulbake, Sanjay Kumar Jain
Abstract of "Ethical Challenges with the Development of Biotechnology-Derived Allergy Therapeutics"
Journal of Long-Term Effects of Medical Implants, Vol.18, 2008, issue 1
Jason Behrmann
Transcending the Skin Barrier to Deliver Peptides and Proteins Using Active Technologies
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 4
Haripriya Kalluri, Anushree Herwadkar, Neha Singh, Ajay K. Banga, Advait Badkar